中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

HBV cccDNA、HBsAg、HBV pgRNA联合检测对恩替卡韦治疗HBeAg阳性慢性乙型肝炎效果的预测价值

王颖 赵奎 秦建忠

戴文聪, 臧梦雅, 袁国盛, 等. 肝动脉灌注化疗及其综合治疗方案对中晚期肝细胞癌患者的临床疗效及预后因素分析[J]. 临床肝胆病杂志, 2023, 39(7): 1592-1599. DOI: 10.3969/j.issn.1001-5256.2023.07.013.
引用本文: 戴文聪, 臧梦雅, 袁国盛, 等. 肝动脉灌注化疗及其综合治疗方案对中晚期肝细胞癌患者的临床疗效及预后因素分析[J]. 临床肝胆病杂志, 2023, 39(7): 1592-1599. DOI: 10.3969/j.issn.1001-5256.2023.07.013.
DAI WC, ZANG MY, YUAN GS, et al. Efficacy of hepatic arterial infusion chemotherapy and its multimodality therapeutic regimens in treatment of patients with advanced hepatocellular carcinoma and related prognostic factors[J]. J Clin Hepatol, 2023, 39(7): 1592-1599. DOI: 10.3969/j.issn.1001-5256.2023.07.013.
Citation: DAI WC, ZANG MY, YUAN GS, et al. Efficacy of hepatic arterial infusion chemotherapy and its multimodality therapeutic regimens in treatment of patients with advanced hepatocellular carcinoma and related prognostic factors[J]. J Clin Hepatol, 2023, 39(7): 1592-1599. DOI: 10.3969/j.issn.1001-5256.2023.07.013.

HBV cccDNA、HBsAg、HBV pgRNA联合检测对恩替卡韦治疗HBeAg阳性慢性乙型肝炎效果的预测价值

DOI: 10.3969/j.issn.1001-5256.2020.05.012
基金项目: 

江苏省自然青年科学基金项目(BK20160338); 

详细信息
  • 中图分类号: R512.62

Value of combined measurement of hepatitis B virus covalently closed circular DNA,HBsAg,and hepatitis B virus pregenomic RNA in predicting the treatment outcome of HBeAg-positive chronic hepatitis B patients treated with entecavir

Research funding: 

 

  • 摘要:

    目的研究血清HBV共价闭合环状DNA(HBV cccDNA)、HBsAg、HBV前基因组RNA(HBV pgRNA)联合检测对恩替卡韦(ETV)治疗HBeAg阳性慢性乙型肝炎(CHB)患者的效果预测价值。方法将2015年5月-2017年5月经苏州大学附属第二医院确诊为HBeAg阳性的87例CHB患者纳入研究。根据患者ETV治疗48周后是否获得完全应答,分为获得组(n=38)和未获得组(n=49)。均采取ETV治疗,疗程48周,观测患者基线及治疗12、24、48周时血清HBV cccDNA、HBsAg、HBV pgRNA的水平。正态分布的计量资料组间比较采用t检验,非正态分布的采用Mann-WhitneyU检验。计数资料组间比较采用χ2检验;等级资料组间比较采用Mann-WhitneyU检验。采用Pearson相关分析探讨肝组织HBV cccDNA与血清HBsAg、HBV pgRNA的相关性。采用多因素logistic回归分析完全应答的预测因素,并采用受试者工作特征曲线(ROC曲线)评价血清HBV cccDNA、HBsAg、HBV pgRNA单独或联合检测对完全应答...

     

  • [1] PAN HY, PAN HY, SONG WY, et al. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis[J]. J Viral Hepat, 2017,24(Suppl 1):29-35.
    [2] PAPATHEODORIDIS GV, SYPSA V, DALEKOS G, et al. Eightyear survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population[J].J Hepatol, 2018, 68(6):1129-1136.
    [3] Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on functional cure of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(8):1693-1701.(in Chinese)中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎临床治愈(功能性治愈)专家共识[J].临床肝胆病杂志,2019, 35(8):1693-1701.
    [4] Chinese Society of Hepatology and Chinese Society of Infectious Disease,Chinese Medical Association. Guidelines for the Prevention and treatment of chronic Hepatitis B(updated V2015)[J]. J Clin Hepatol, 2015, 31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015, 31(12):1941-1960.
    [5] YAO GB, REN H, XU DZ, et al. Continuous treatment of entecavir in patients with chronic hepatitis B for 3 years[J]. Chin J Hepatol, 2009,17(12):884-886.(in Chinese)姚光弼,任红,徐道振,等.慢性乙型肝炎患者持续应用恩替卡韦的疗效[J].中华肝脏病杂志,2009, 17(12):884-886.
    [6] VLACHOGIANNAKOS J, PAPATHEODORIDIS GV. Optimal therapy of chronic hepatitis B:How do I treat HBeAg-positive patients?[J]. Liver Int, 2015, 35(Suppl 1):100-106.
    [7] GUO Y, LI Y, MU S, et al. Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication[J]. J Med Virol, 2009, 81(7):1177-1183.
    [8] SPANGENBERG HC, THIMME R, BLUM HE. Tracking cccDNA in chronic HBV infection[J]. Hepatology, 2004, 39(6):1736-1738.
    [9] CHONG CL, CHEN ML, WU YC, et al. Dynamics of HBV cccDNA expression and transcription in different cell growth phase[J]. J Biomed Sci, 2011, 18:96.
    [10] WU M, LI J, YUE L, et al. Establishment of Cre-mediated HBV recombinant cccDNA(rcccDNA)cell line for cccDNA biology and antiviral screening assays[J]. Antiviral Res, 2018,152:45-52.
    [11] BUTLER EK, GERSCH J, MCNAMARA A, et al. Hepatitis B virus serum DNA andRNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection[J]. Hepatology, 2018, 68(6):2106-2117.
    [12] GAO N, WU RH, WANG XM, et al. Predictive value of HBsAg quantitative test for prognosis of patients with chronic severe hepatitis B[J]. J Clin Hepatol, 2016, 32(4):192-194.(in Chinese)高娜,吴瑞红,王晓美,等.HBsAg定量检测对慢性重型乙型肝炎患者预后的预测价值[J].临床肝胆病杂志,2016, 32(4):192-194.
    [13] ZHOU YQ, LI C. Value of HBsAg quantification in individualized anti-HBV treatment with nucleos(t)ide analogues[J]. J Clin Hepatol, 2019, 35(8):1821-1823.(in Chinese)周友乾,李翠.HBsAg定量在核苷(酸)类似物个体化抗HBV治疗中的应用价值[J].临床肝胆病杂志,2019, 35(8):1821-1823.
    [14] PENG H, WEI F, LIU JY, et al. Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification:A meta-analysis[J]. Hepatol Int, 2015, 9(4):543-557.
    [15] van BOMMMEL F, BERG T. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B[J]. Liver Int, 2018, 38(Suppl 1):90-96.
    [16] TAN N, LUO H, XU XY. Significance of hepatitis B virus pregenomic RNA in the progression of chronic hepatitis B[J]. J Clin Hepatol, 2018, 34(10):2221-2223.(in Chinese)谭宁,罗皓,徐小元.HBV pgRNA在慢性乙型肝炎进程中的可能意义[J].临床肝胆病杂志,2018, 34(10):2221-2223.
    [17] ZHANG S, SUN J, XING HC. Progress on new anti-hepatitis B viral drugs[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2019, 13(1):6-11.(in Chinese)张珊,孙静,邢卉春.新型抗乙型肝炎病毒药物研究进展[J/CD].中华实验和临床感染病杂志(电子版),2019, 13(1):6-11.
    [18] CAREY I, GERSCH J, WANG B, et al. Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy[J]. Hepatology, 2019.[Online ahead of print].
    [19] YIN XR, FAN R, HOU JL. A 10-year prospective, random, observational study involving 24 countries in the world for long-term treatment of chronic hepatitis B with entecavir or other oral antiviral drugs[J]. J Clin Hepatol, 2019, 35(9):2005.(in Chinese)尹雪如,樊蓉,侯金林.一项为期10年、涉及全球24国的恩替卡韦或其他口服抗病毒药物长期治疗慢性乙型肝炎的前瞻性、随机、观察性研究结果[J].临床肝胆病杂志,2019, 35(9):2005.
  • 期刊类型引用(5)

    1. 康志龙,周益民,宋燕州,张昆,苏一男,魏文平,赵新,李志伟. 靶向免疫治疗联合经肝动脉灌注化疗治疗不可切除肝细胞癌的临床效果及转化治疗的影响因素. 中国医学创新. 2025(01): 47-51 . 百度学术
    2. 许海明,胡永奎,梁平,钟腾猛,陆炳站. 中晚期肝癌患者经动脉化疗栓塞治疗后短期效果及长期预后的影响因素分析. 大医生. 2025(06): 27-31 . 百度学术
    3. 彭林辉,陈涛,徐云修修,王捷,陈捷,李永,黄拼搏,钟国平,陈茜,叶聪婷,陈亚进. mFOLFOX7方案全身化疗联合卡瑞利珠单克隆抗体和阿帕替尼治疗肝细胞癌合并Vp4型门静脉癌栓的疗效. 中华消化外科杂志. 2024(02): 265-271 . 百度学术
    4. 李洁,李瑞娟,鲁志兵,曾筱怡. 肝动脉灌注化疗联合程序性死亡受体1抗体及仑伐替尼治疗晚期肝癌合并门静脉癌栓的效果. 中国当代医药. 2024(26): 43-46+51 . 百度学术
    5. 黄乾鑫,神斌,肖晋昌,高志康,吕墩涛,李艳,徐浩,张庆桥. 载药微球经导管动脉化疗栓塞术联合肠系膜上动脉灌注化疗治疗肝细胞癌合并门静脉癌栓的效果分析. 临床肝胆病杂志. 2024(12): 2457-2463 . 本站查看

    其他类型引用(0)

  • 加载中
计量
  • 文章访问数:  1443
  • HTML全文浏览量:  61
  • PDF下载量:  186
  • 被引次数: 5
出版历程
  • 收稿日期:  2019-11-20
  • 出版日期:  2020-05-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回